{"transactions":[{"id":2633832,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-14T21:32:17.000Z","date":"2021-07-13","kind":"sale","acquired":false,"shares":2631,"price":16.9801,"value":44674.6431,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on July 2, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.9755 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":147447,"source":{"system":"sec-edgar","filing":"0001209191-21-046683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121046683/doc4.xml","form_type":"4"}},{"id":2639114,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-07-07T22:03:57.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-21-045899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121045899/doc4.xml","form_type":"4"}},{"id":2639113,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-07-07T22:03:57.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":150078,"source":{"system":"sec-edgar","filing":"0001209191-21-045899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121045899/doc4.xml","form_type":"4"}},{"id":2685880,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2021-06-03T01:49:08.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001209191-21-037484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037484/doc4.xml","form_type":"4"}},{"id":2685879,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:49:08.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":6800,"price":22.2649,"value":151401.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":144078,"source":{"system":"sec-edgar","filing":"0001209191-21-037484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037484/doc4.xml","form_type":"4"}},{"id":2685878,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:49:08.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":31114,"price":21.4954,"value":668807.8756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.01 to $21.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":150878,"source":{"system":"sec-edgar","filing":"0001209191-21-037484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037484/doc4.xml","form_type":"4"}},{"id":2685877,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:49:08.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":4885,"price":23.5705,"value":115141.8925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.33 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":181992,"source":{"system":"sec-edgar","filing":"0001209191-21-037484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037484/doc4.xml","form_type":"4"}},{"id":2685876,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:49:08.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":9115,"price":22.7124,"value":207023.526,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.24 to $23.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":186877,"source":{"system":"sec-edgar","filing":"0001209191-21-037484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037484/doc4.xml","form_type":"4"}},{"id":2685875,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:49:08.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":87500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":195992,"source":{"system":"sec-edgar","filing":"0001209191-21-037484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121037484/doc4.xml","form_type":"4"}},{"id":2811554,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-02","kind":"exercise","acquired":false,"shares":8297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":24892,"derivative":{"underlying":"Common Stock","underlying_shares":8297},"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811553,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-01","kind":"exercise","acquired":false,"shares":20600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":41200,"derivative":{"underlying":"Common Stock","underlying_shares":20600},"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811552,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":28400,"derivative":{"underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811551,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":99500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date."}],"balance_after":99500,"derivative":{"exercise_price":24.06,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":99500},"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811550,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-02","kind":"tax_withholding","acquired":false,"shares":2280,"price":23.25,"value":53010.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":108492,"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811549,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-02","kind":"exercise","acquired":true,"shares":8297,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":110772,"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811548,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":5660,"price":24.06,"value":136179.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":102475,"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":2811547,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:42:09.000Z","date":"2021-03-01","kind":"exercise","acquired":true,"shares":20600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":108135,"source":{"system":"sec-edgar","filing":"0001209191-21-017555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121017555/doc4.xml","form_type":"4"}},{"id":3087217,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2020-07-07T23:25:41.000Z","date":"2020-07-02","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-20-041565","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120041565/doc4.xml","form_type":"4"}},{"id":3087216,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-07-07T23:25:41.000Z","date":"2020-07-02","kind":"tax_withholding","acquired":false,"shares":1360,"price":1.5,"value":2040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":87535,"source":{"system":"sec-edgar","filing":"0001209191-20-041565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120041565/doc4.xml","form_type":"4"}},{"id":3087215,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-07-07T23:25:41.000Z","date":"2020-07-02","kind":"exercise","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":88895,"source":{"system":"sec-edgar","filing":"0001209191-20-041565","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120041565/doc4.xml","form_type":"4"}},{"id":3123232,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2020-06-03T20:43:53.000Z","date":"2020-06-01","kind":"exercise","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":87500,"derivative":{"underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001209191-20-034065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120034065/doc4.xml","form_type":"4"}},{"id":3123231,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-06-03T20:43:53.000Z","date":"2020-06-01","kind":"tax_withholding","acquired":false,"shares":24045,"price":1.32,"value":31739.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":82895,"source":{"system":"sec-edgar","filing":"0001209191-20-034065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120034065/doc4.xml","form_type":"4"}},{"id":3123230,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-06-03T20:43:53.000Z","date":"2020-06-01","kind":"exercise","acquired":true,"shares":87500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":106940,"source":{"system":"sec-edgar","filing":"0001209191-20-034065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120034065/doc4.xml","form_type":"4"}},{"id":3226466,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:20:50.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":33189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":33189,"derivative":{"underlying":"Common Stock","underlying_shares":33189},"source":{"system":"sec-edgar","filing":"0001209191-20-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/doc4.xml","form_type":"4"}},{"id":3226465,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-04T21:20:50.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":116160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date."}],"balance_after":116160,"derivative":{"exercise_price":1.26,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":116160},"source":{"system":"sec-edgar","filing":"0001209191-20-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/doc4.xml","form_type":"4"}},{"id":3226464,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:20:50.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":20600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":61800,"derivative":{"underlying":"Common Stock","underlying_shares":20600},"source":{"system":"sec-edgar","filing":"0001209191-20-016065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/doc4.xml","form_type":"4"}},{"id":3226463,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-03-04T21:20:50.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":5512,"price":1.26,"value":6945.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":19440,"source":{"system":"sec-edgar","filing":"0001209191-20-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/doc4.xml","form_type":"4"}},{"id":3226462,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-03-04T21:20:50.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":20600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":24952,"source":{"system":"sec-edgar","filing":"0001209191-20-016065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/doc4.xml","form_type":"4"}},{"id":3384356,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2019-10-31T20:18:07.000Z","date":"2019-10-30","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":175000,"derivative":{"underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-19-054623","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119054623/doc4.xml","form_type":"4"}},{"id":3467354,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2019-07-03T20:44:45.000Z","date":"2019-07-02","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest over a period of four years, with 25% vesting on the first, second, third and fourth anniversaries of the date of grant, beginning on July 2, 2019 and subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-041173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119041173/doc4.xml","form_type":"4"}},{"id":3467353,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-07-03T20:44:45.000Z","date":"2019-07-02","kind":"tax_withholding","acquired":false,"shares":1648,"price":2.34,"value":3856.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":4352,"source":{"system":"sec-edgar","filing":"0001209191-19-041173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119041173/doc4.xml","form_type":"4"}},{"id":3467352,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-07-03T20:44:45.000Z","date":"2019-07-02","kind":"exercise","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-19-041173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119041173/doc4.xml","form_type":"4"}},{"id":3617872,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":137330,"kind":"person","name":"Gordon David N.","position":1,"cik":"0001751167","reported_name":"Gordon David N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2019-03-04T23:10:21.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":82400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":82400,"derivative":{"underlying":"Common Stock","underlying_shares":82400},"source":{"system":"sec-edgar","filing":"0001209191-19-015888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119015888/doc4.xml","form_type":"4"}}]}